Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Eric Baudin
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer
Abstract Patients with advanced malignant adrenal tumors face poor prognoses with limited treatment options. Emerging data suggest that these rare tumors exhibit immunogenicity, potentially benefiting from intensified immunotherapy.
[ 177 Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial
Get full text access Log in, subscribe or purchase for full access. References 1. Pavel, M ∙ Öberg, K ∙ Falconi, M ∙ et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol. 2020; 31:844-860 2. Kos-Kudła, B ∙ Castaño, JP ∙ Denecke, T ∙ et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours J Neuroendocrinol. 2023; 35, e13343 3.
Outcome of combination chemotherapy for metastatic adrenocortical carcinoma
Background: Etoposide, doxorubicin, cisplatin, and mitotane (EDP-M) is considered the firstline treatment for metastatic adrenocortical carcinoma (ACC). However, a considerable proportion of patients experience serious adverse events and impact of the EDP-M regimen on patient survival remains unclear. On that ground, it has been hypothesized that omitting doxorubicin from the EDP-M protocol would increase tolerability without a relevant loss of efficacy.
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
Summary No randomised controlled trial has ever been done in patients with metastatic phaeochromocytomas and paragangliomas. Preclinical and first clinical evidence suggested beneficial effects of sunitinib. We aimed to evaluate the safety and efficacy of sunitinib in patients with metastatic phaeochromocytomas and paragangliomas. FIRSTMAPPP is a multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial done at 14 academic centres across four European countries.
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
Summary No randomised controlled trial has ever been done in patients with metastatic phaeochromocytomas and paragangliomas. Preclinical and first clinical evidence suggested beneficial effects of sunitinib. We aimed to evaluate the safety and efficacy of sunitinib in patients with metastatic phaeochromocytomas and paragangliomas. FIRSTMAPPP is a multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial done at 14 academic centres across four European countries.
The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Hallet J. Law C.H.L. Cukier M. Saskin R. Liu N. Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015; 121: 589-597https://doi.org/10.1002/cncr.29099 Dasari A. Shen C. Halperin D. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017; 3: 1335-1342https://doi.org/10.1001/jamaoncol.2017.0589 Zamora V. Cabanne A.
Surgery in the context of kinase inhibitor therapy for locally invasive thyroid cancer
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Abstract Kinase inhibitors (KI) for advanced and aggressive forms of differentiated, medullary and anaplastic thyroid carcinoma have been shown to provide significant tumor response, locally and in distant metastases.
European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors
Adrenocortical carcinoma (ACC) is a rare and in most cases steroid hormone producing tumor with variable prognosis. The purpose of these guidelines is to provide clinicians with best possible evidence-based recommendations for clinical management of patients with ACC based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Eric
Contact Eric, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack